保留乳头乳晕复合体乳腺癌根治即刻胸大肌包裹假体植入乳房重建

目的 探讨保留乳头乳晕复合体(NAC)的乳腺癌改良根治术即刻胸大肌包裹假体植入乳房重建的可行性.方法 对28例0、I、II期乳腺癌行保留皮肤的乳腺癌改良根治术后,即刻于胸大肌后方植入硅胶假体重建乳房,并根据冰冻切片结果决定是否保留NAC.结果 28例早期乳腺癌均保留了NAC,术后随访2～18个月(中位随访期:15个月),外观良好,双侧乳房对称,优良率达96.5%;均无局部复发或远处转移,无明显术后并发症.结论 保留NAC的乳腺癌改良根治术后用硅胶假体行即刻乳房重建,能达到满意的乳房美容效果,是治疗早期乳腺癌安全可行的方法.     

保留皮肤的乳腺癌改良根治术后一期乳房假体再造

目的探讨用硅胶假体植入法修复乳腺癌改良根治术后乳房缺失的疗效。方法2005年6月至11月,10例患者行保留皮肤的乳腺癌改良根治术后,同期于胸大肌后植入硅胶假体再造乳房,并根据冰冻结果决定是否保留乳头乳晕复合体。结果本组病人术后无伤口积液感染,皮肤坏死及异物反应等。10例患者美观效果均满意,其中有4例保留乳头乳晕复合体。所有病人进行术后随访。随访时间为1～6个月。未发现有远处转移和局部复发。无上肢水肿及功能障碍。结论保留皮肤的乳腺癌改良根治术后用硅胶假体行一期乳房再造,具有创伤小、安全、简单、恢复快的特点;再造后乳房美观,效果满意。     

保留皮肤的乳腺癌改良根治术后即刻乳房假体再造的临床应用

目的探讨保留皮肤的乳腺癌改良根治术后即刻乳房假体再造的临床应用价值。方法我院2006年1月至2009年12月期间收治的28例乳腺癌患者行保留皮肤的乳腺癌改良根治术后,同时于胸大肌后置入硅胶假体再造乳房,对围手术期结果、乳房外观评价以及随访结果进行分析。结果本组28例患者均行腋窝淋巴结清扫术,清除淋巴结数目为14~32枚,中位数为21枚。手术时间为117~140 min(平均126 min),术中出血量为82~124 ml(平均98 ml),术后引流管拔除时间为3~5 d。所有患者术后均无伤口积液、感染、皮肤坏死、异物反应等,22例保留了乳头乳晕复合体的患者均无乳头乳晕缺血、坏死。患者术后乳房外观评价中,10例为优,18例为良,优良率为100%。所有患者术后均获随访,随访时间为12~48个月(中位随访时间24个月),未发现有远处转移和局部复发,无上肢水肿及功能障碍。所有患者乳房外观及手感满意,无纤维包膜挛缩。结论保留皮肤的乳腺癌改良根治术后用硅胶假体行即刻乳房再造具有创伤小、安全、手术操作简单、术后恢复快的特点,再造后乳房美观,效果满意,值得临床推广。     

保留乳头乳晕的乳房全切术后带蒂大网膜联合假体乳房一期重建23例

目的探讨保留乳头乳晕的乳房全切术后带蒂大网膜联合假体一期乳房重建的可行性和效果。 方法选择湖南省肿瘤医院乳腺二科2013年8月至2015年9月收治的0、Ⅰ、Ⅱ期乳腺癌患者23例,所有患者按肿瘤切除原则先行保留乳头乳晕的乳房全切术,取上腹部小切口游离带蒂大网膜联合凝胶假体植入胸大小肌之间行乳房一期重建。 结果23例大网膜组织瓣全部成活,随访3~25个月,无一例假体移位、破裂,重建乳房外观自然、柔软、形态良好,其中2例导管内癌患者因术后预留乳头乳晕部位皮肤较薄出现了乳头缺血,颜色变黑,随访3个月,未见坏死。随访期间未见一例复发。 结论保留乳头乳晕的改良根治术后带蒂大网膜联合假体一期乳房重建是一种安全可行且美容效果良好的手术方法。     

保留乳头的乳腺癌根治术即乳房重建术

目的：探讨早期乳腺癌行保留乳头的改良根治、即期硅胶假体植入乳房重建术的可行性.方法：利用早期乳腺癌极少侵犯乳头、乳晕及皮肤的特点，切除病灶及其上方部分皮肤后行皮下乳房切除＋腋淋巴结清扫术，并与硅胶假体植入术有机结合，达到一期重建乳房的目的.结果：对18例早期乳腺癌患者采用上述术式重建乳房后客观评价效果优良和尚好者达94.4%，主观评价效果优良和尚好者达100%，术后随访12～36个月，所有病例均无局部复发及远处转移.结论：保留乳头的非定型式乳腺癌根治与即期硅胶假体植入乳房重建术是治疗Ⅰ期及部分Ⅱ期乳腺癌安全可行的方法。     

乳腺癌一期胸大肌前或后植入假体行乳房重建53例回顾性分析

目的:探讨乳腺癌全腺体切除后在胸大肌前皮肤筋膜脂肪瓣下直接植入假体行乳房重建手术模式的可行性。方法:回顾性分析2017年1月至2020年6月期间,在茂名市人民医院乳腺科接受不保留或保留乳头乳晕复合体的乳房皮下切除术联合一期植入假体行乳房重建的乳腺癌患者53例,分胸大肌前植入组（31例）及胸大肌后方植入组（22例）,对两...     

保留乳头乳晕复合体乳癌术后即时扩展型背阔肌肌皮瓣乳房再造

目的:探讨保留乳头乳晕复合体的乳腺癌改良根治术后行即时以扩展型背阔肌肌皮瓣行乳房再造的安全性和手术技巧。方法:28例早期乳腺癌患者行保留乳头乳晕复合体乳腺癌改良根治术,术后即刻使用扩展型背阔肌肌皮瓣再造乳房。术中改进:注意保护乳房皮肤的感觉神经、保留胸背神经及二级分支,采取皮瓣翻转法乳房塑型,行腋窝填塞和腋前皱襞的重建以及切取皮瓣的组织量大于切除的20%～50%腺体量等。结果:28例即时乳房再造全部获得成功。随访12～36个月,均生存,无局部复发,其中1例术后10个月骨转移,1例2年后肺转移;美学效果:优18例,良6例,一般2例,差2例;再造乳房皮肤的感觉、乳头的竖起功能存在,自然下垂,外形对称,腋窝饱满,患侧肢体运动范围较常规改良根治术明显增大。结论:对于选择合适的病例,保留乳头乳晕复合体的乳腺癌改良根治术后应用即时扩展型背阔肌肌皮瓣再造术安全、有效,术中几点合理的技术改进可以明显提高再造乳房的质量和自然度。     

胸大肌筋膜在乳腺癌乳房切除后即刻乳房重建中的应用

目的:探讨胸大肌筋膜在乳腺癌乳房切除后即刻乳房重建中的应用价值。方法:回顾分析2014年5月—2016年9月接受保留乳头乳晕复合体的皮下腺体切除与即刻乳房重建的18例早期乳腺癌患者临床资料。患者均采用胸大肌及其筋膜覆盖并包裹假体行乳房重建,即首先从自胸骨旁及锁骨下向外侧游离剥离胸大肌筋膜,然后在胸大小肌之间植入假体,最后用游离的胸大肌筋膜缝合胸大肌外侧缘,牢固包裹假体。结果:18例乳房重建手术均取得成功,经过12~40个月随访,所有患者未发现复发、转移,重建乳房对称性好、形态自然,未发现假体移位、挛缩,术后外观评价优良率100%。结论:对于部分早期乳腺癌患者,实施保留乳头乳晕复合体的皮下腺体切除、利用胸大肌及其筋膜覆盖假体的即刻乳房重建方法简单易行,重建乳房美容效果好,并发症少。     

����Ƥ�������ٰ������������󼴿̼���ֲ�������鷿��̽��

目的用安全、简便的方法解决乳腺癌根治术后乳房缺损问题。方法2002年4月至2004年9月,在行保留皮肤的乳腺癌改良根治术后同期于胸大肌后植入Meter或Beck假体,即时再造乳房。根治术时根据冰冻结果决定是否保留乳头乳晕复合体。结果32例病人中,23例行Meter单囊假体植入,9例行Beck双囊可扩张假体植入,5例保留乳头乳晕复合体,均获得满意效果。32例病人中经病理证实15例为浸润性导管癌,11例为浸润性小叶癌,4例为浸润性导管癌同时合并浸润性小叶癌,1例为乳管内乳头状瘤病伴部分癌变,1例为浸润性小叶癌保乳术后复发。结论保留皮肤的乳腺癌改良根治术后运用假体植入法行Ⅰ期乳房再造,创伤小、安全、快速,恢复期短,手术操作简单易行,即时效果满意。     

保留乳头乳晕复合体的一期硅胶假体乳房再造在乳腺肿瘤手术中的应用

目的：探讨保留乳头乳晕复合体（NAC）的一期硅胶假体乳房再造在乳腺良恶性肿瘤乳房切除术后乳房缺损中应用的可行性。 方法：选取2008年1月—2012年11月乳腺良、恶性肿瘤患者各15例,行乳房切除术后一期胸大肌包裹硅胶假体乳房再造,术中保留NAC;术后随访13~48个月,观察患者乳房美容效果、并发症及临床疗效。 结果：30例患者中28例对术后乳房外形满意,术后1.5、2年出现假体包膜挛缩、假体渗漏各1例,无与保留NAC相关的肿瘤残留、复发或转移。 结论：保留NAC的乳腺肿瘤乳房切除术后一期硅胶乳房假体再造能在治愈患者乳腺肿瘤的同时又满足了患者乳房外形美观的要求,且不增加并发症、肿瘤残留、复发或转移的发生率。     

扩张后假体置入乳房再造术的临床应用

目的 介绍扩张后假体置入乳房再造术在乳癌改良根治术后乳房缺损、单纯乳腺腺体切除及乳房不对称畸形患者中的应用.方法 将圆形扩张器埋置于胸大肌深面,超量注水30%～50%扩张后,维持3个月以上,二期将扩张器更换为乳房假体.结果 临床应用9例,13侧乳房,其中乳癌改良根治术后乳房缺损2例2侧,单纯乳腺腺体切除4例8侧,乳房不对称畸形3例3侧,最长随访2年,效果满意.结论 扩张后假体置入乳房再造可以使患者获得接近对侧乳房的形态和大小,且没有再造术附加供区的创伤.放疗会增加并发症的发生,需要放疗的患者慎用此法.     

乳腺癌全乳切除术后I/II期假体植入重建乳房

【摘要】　目的　总结乳腺癌全乳切除术后I/II期硅胶假体植入重建乳房的临床经验。方法 对2005年6月~2012年12月本院收治的87例行全乳切除术后I/II期硅胶假体植入乳房重建的乳腺癌病例进行回顾性分析。结果 87例假体植入手术均取得成功,I/II期植入后客观评价:Ⅰ期优、良及尚好为95.2%,主观评价优、良及尚好为93.6%;Ⅱ期的主客观评价均为100%。I期植入中出现2例乳头乳晕坏死,需行假体取出术,1例乳头坏死,疤痕愈合;随访2~92个月,所有病例均没有发现有局部的复发及远处转移,也未发现假体的移位、包膜挛缩。结论　乳腺癌全乳切除术后Ⅰ/Ⅱ期假体植入重建乳房,能满足乳房切除术后的美容要求,是治疗早期乳腺癌安全可行的方法。     

保留乳头乳晕的乳腺癌改良根治术后即刻假体乳房再造的效果

目的:探讨硅胶假体在保留乳头乳晕的乳腺癌改良根治术后即刻乳房再造的效果。方法:2016年1月至2018年1月,湖南省郴州市第一人民医院乳腺甲状腺外科收治30例女性乳腺癌患者,年龄30~55岁,平均42岁;分为两组。观察组15例采用保留乳头乳晕的乳腺癌改良根治术联合即刻假体乳房再造,对照组15例仅行乳腺癌改良根治术。比较...     

乳腺癌保留皮肤改良根治并即刻假体再造与传统改良根治术的疗效比较

目的 比较乳腺癌保留皮肤改良根治并即刻假体再造和传统改良根治术的治疗效果.方法 对2004年1月至2008年12月手术治疗的530例0～Ⅲa期女性乳腺癌患者病例资料进行回顾性分析.530例中,91例行乳腺癌保留皮肤改良根治并即刻假体再造,439例行传统改良根治术.通过比较两组患者术后并发症、局部复发率、远处转移率、病死率的差异,评价乳腺癌保留皮肤改良根治并即刻假体重建与传统改良根治术的疗效.结果 即刻假体再造组随访患者84例,中位随访时间35个月,局部复发率2.4%,远处转移率8.3%,病死率6.0%;改良根治组随访患者439例,中位随访时间36个月,局部复发率3.3%,远处转移率9.5%,病死率6.5%.随访期间两组复发率、转移率、病死率的差异均无统计学意义(P＞0.05).即刻假体再造组术后美观效果随访12个月,医生和患者评估的良好率分别为93%、87%.结论 乳腺癌保留皮肤改良根治并即刻假体再造可以达到和传统改良根治术相当的疗效,并可显著改善患者术后乳房外形美观及生活质量.

Abstract：

Objective To compare the therapy efficiency of immediate implanting breast reconstruction after skin sparing mastectomy and modified radical mastectomy in breast cancer. Methods The data of 530 female patients with early of stage 0 to Ⅲ a breast cancer was retrospectively analyzed, from January 2004 to Decembet 2008. Among the patients,91 patients operated with skin sparing mastectomy and immediate implanting breast reconstruction ( Group of immediate implanting reconstruction), and 439 patients were with modified radical mastectomy (Group of modified radical mastectomy ). By comparing complications, local recurrence, distant metastases and mortality rates between the two groups, the research was done to evaluate the therapy efficiency. Results In the group of immediate implanting reconstruction,84 patients completed follow-up with the median follow-up time of 35 months ( 14-72 months) while the local recurring rate was 2. 4%, distant metastasis rate was 8. 3% and mortality rate was 6. 0%. In the group of modified radical mastectomy, 398 patients completed follow-up with the median follow-up time of 36 months ( 12-74 months) while the local recurring rate was 3.3%, distant metastasis rate was 9. 5% and mortality rate was 6. 5%. Therefore there was no obvious statistic difference between the two groups in local recurring rate, distant metastasis rate and mortality rate (P ＞ 0. 05 ). Evaluation of aesthetic results was done in the 84 patients after immediate implanting reconstruction for 12 months which was 93% as good or excellent by surgeons while 87% by patients. Surgeons and patients were both satisfied with the breast appearance. Conclusions For patients with early stage breast cancer, combining standard postoperative therapy, skin sparing mastectomy and immediate implanting reconstruction could achieve the same effect as the traditional modified radical mastectomy, while reconstruction would bring about better appearance and higher quality of life.     

Skin-sparing mastectomy with staged tissue expander reconstruction using a silicone gel prosthesis and contralateral endoscopic breast augmentation

Women with an A or B cup-size breast with no ptosis or glandular ptosis underwent a skin-sparing mastectomy through a periareolar incision. A submuscular tissue expander was placed for immediate reconstruction. The periareolar incision was closed using a modified pursestring technique. The reconstructed breast was expanded to a C cup size. The expander was removed and replaced with a silicone gel prosthesis. At the time of tissue expander removal, the contralateral breast underwent endoscopic augmentation. Nipple-areolar reconstruction was performed during a third stage to cover the mastectomy scar. Implant reconstruction of the breast frequently results in a breast mound that has greater upper breast fullness than the opposite breast. By augmenting the opposite breast, better symmetry is achieved. Burden WR. Skin-sparing mastectomy with staged tissue expander reconstruction using a silicone gel prosthesis and contralateral endoscopic breast augmentation.     

Skin-sparing mastectomy in the UK--a review of current practice

BACKGROUND: Skin-sparing mastectomy (was first described in 1991 and has achieved popularity because it facilitates immediate breast reconstruction, preserving the infra-mammary fold and breast envelope. Little is known about the use of skin-sparing mastectomy in the UK. METHODS: All members of the BASO Breast Specialty Group were contacted in June 2001 with a questionnaire to determine the popularity of skin-sparing mastectomy, techniques used, indications, contra-indications and outcomes. RESULTS: Of 300 questionnaires sent, 130 were returned by September 2001. The number of respondents using skin-sparing mastectomy increased from 27 (21%) in 1997 to 95 (73%) in 2001. Of respondents, 35 (23%) avoided skin-sparing mastectomy because of their uncertainty about the benefits (22/35), indications (16/35) or oncological safety (13/35). Where skin-sparing mastectomy was performed, it was combined with immediate breast reconstruction in 90% of cases, using latissimus dorsi (84%), subpectoral (70%) or TRAM flap reconstruction (54%). Skin-sparing mastectomy was performed by breast surgeons alone (62%), or with a plastic surgeon (47%) and the preferred incisions were peri-areolar (68%) and elliptical (26%). Most respondents used skin-sparing mastectomy for prophylaxis, in situ cancer and early invasive disease and avoided skin-sparing mastectomy in patients with skin tethering (62%), where radiotherapy was planned (49%) and in smokers (28%). Complications seen by respondents included skin envelope necrosis (68%), haematoma formation (46%), cosmetic failure (41%) and local recurrence (12%). CONCLUSIONS: Skin-sparing mastectomy is becoming popular in the UK, but experience is limited. The variation in indications and techniques indicate the need to establish evidence-based guidelines for the wider practice of skin-sparing mastectomy in the UK.